- PR Newswire•3 months agoAvanir Pharmaceuticals to Present Data on ONZETRA™ Xsail™ at American Headache Society (AHS) 2016 Annual Scientific Meeting
ALISO VIEJO, Calif., June 9, 2016 /PRNewswire/ -- Avanir Pharmaceuticals , Inc. today announced that the company will be presenting results from several studies about ONZETRA™ Xsail™ (sumatriptan nasal ...
- PR Newswire•3 months agoNUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
ALISO VIEJO, Calif., June 8, 2016 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced the publication of full results from the PRISM II study, which demonstrated significant improvement of pseudobulbar affect (PBA) following treatment with NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules in patients with Alzheimer's disease (AD) and other dementias, stroke and traumatic brain injury (TBI). PBA is a condition characterized by sudden and uncontrollable outbursts of crying and/or laughing resulting from certain neurologic diseases or brain injury. NUEDEXTA is the only pharmaceutical agent approved by the U.S. Food and Drug Administration for the treatment of PBA.
- PR Newswire•3 months agoAVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA™ Xsail™ for the Acute Treatment of Migraine in Adults
ALISO VIEJO, Calif., May 16, 2016 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced ONZETRA™ Xsail™ (sumatriptan nasal powder) is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved ONZETRA Xsail in January 2016 for the acute treatment of migraine with or without aura in adults. The approval was based on data from phase II and phase III trials, safety data from more than 300 patients and reference data from the extensive clinical use of sumatriptan over the past 20 years.
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|